Literature DB >> 30294852

Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles.

Mirco Ponzoni1, Flavio Curnis2, Chiara Brignole1, Silvia Bruno3, Daniela Guarnieri4, Leopoldo Sitia4, Roberto Marotta5, Angelina Sacchi2, Matteo Bauckneht6, Ambra Buschiazzo6, Andrea Rossi7, Daniela Di Paolo1, Patrizia Perri1, Alessandro Gori8, Angela R Sementa7, Laura Emionite9, Michele Cilli9, Roberto Tamma10, Domenico Ribatti10, Pier Paolo Pompa4, Cecilia Marini11,12, Gianmario Sambuceti6,11, Angelo Corti2, Fabio Pastorino1.   

Abstract

Targeted delivery of anticancer drugs with nanocarriers can reduce side effects and ameliorate therapeutic efficacy. However, poorly perfused and dysfunctional tumor vessels limit the transport of the payload into solid tumors. The use of tumor-penetrating nanocarriers might enhance tumor uptake and antitumor effects. A peptide containing a tissue-penetrating (TP) consensus motif, capable of recognizing neuropilin-1, is here fused to a neuroblastoma-targeting peptide (pep) previously developed. Neuroblastoma cell lines and cells derived from both xenografts and high-risk neuroblastoma patients show overexpression of neuropilin-1. In vitro studies reveal that TP-pep binds cell lines and cells derived from neuroblastoma patients more efficiently than pep. TP-pep, after coupling to doxorubicin-containing stealth liposomes (TP-pep-SL[doxorubicin]), enhances their uptake by cells and cytotoxic effects in vitro, while increasing tumor-binding capability and homing in vivo. TP-pep-SL[doxorubicin] treatment enhances the Evans Blue dye accumulation in tumors but not in nontumor tissues, pointing to selective increase of vascular permeability in tumor tissues. Compared to pep-SL[doxorubicin], TP-pep-SL[doxorubicin] shows an increased antineuroblastoma activity in three neuroblastoma animal models mimicking the growth of neuroblastoma in humans. The enhancement of drug penetration in tumors by TP-pep-targeted nanoparticles may represent an innovative strategy for neuroblastoma.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug delivery; nanoparticles; neuroblastoma; targeted therapy; tumor penetration

Mesh:

Substances:

Year:  2018        PMID: 30294852     DOI: 10.1002/smll.201802886

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  4 in total

1.  Extracts from Cell Suspension Cultures of Strawberry (Fragaria x ananassa Duch): Cytotoxic Effects on Human Cancer Cells.

Authors:  Simona Lucioli; Fabio Pastorino; Paolo Nota; Giulia Ballan; Andrea Frattarelli; Alessia Fabbri; Cinzia Forni; Emilia Caboni
Journal:  Molecules       Date:  2019-05-04       Impact factor: 4.411

2.  Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy.

Authors:  Chiara Brignole; Veronica Bensa; Nuno A Fonseca; Genny Del Zotto; Silvia Bruno; Ana F Cruz; Fabiana Malaguti; Barbara Carlini; Fabio Morandi; Enzo Calarco; Patrizia Perri; Vera Moura; Laura Emionite; Michele Cilli; Francesco De Leonardis; Annalisa Tondo; Loredana Amoroso; Massimo Conte; Alberto Garaventa; Angela R Sementa; Maria V Corrias; Mirco Ponzoni; Joao N Moreira; Fabio Pastorino
Journal:  J Exp Clin Cancer Res       Date:  2021-06-02

3.  The Olive Leaves Extract Has Anti-Tumor Effects against Neuroblastoma through Inhibition of Cell Proliferation and Induction of Apoptosis.

Authors:  Fabio Morandi; Veronica Bensa; Enzo Calarco; Fabio Pastorino; Patrizia Perri; Maria Valeria Corrias; Mirco Ponzoni; Chiara Brignole
Journal:  Nutrients       Date:  2021-06-24       Impact factor: 5.717

4.  The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma.

Authors:  Enrico Rango; Fabio Pastorino; Chiara Brignole; Arianna Mancini; Federica Poggialini; Salvatore Di Maria; Claudio Zamperini; Giulia Iovenitti; Anna Lucia Fallacara; Samantha Sabetta; Letizia Clementi; Massimo Valoti; Silvia Schenone; Adriano Angelucci; Mirco Ponzoni; Elena Dreassi; Maurizio Botta
Journal:  Biomedicines       Date:  2022-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.